Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial.

ABSTRACT:

Objective

To test the hypothesis that ticagrelor plus aspirin is safe and superior to clopidogrel plus aspirin for reducing high platelet reactivity at 90 days and stroke recurrence in patients with minor stroke or transient ischaemic attack, particularly in carriers of the CYP2C19 loss-of-function allele and patients with large artery atherosclerosis.

Design

Open label, blinded endpoint, randomised controlled phase II trial.

Setting

Prospective studies conducted at 26 centres in China, August 2015 to March 2017.

Participants

675 patients with acute minor stroke or transient ischaemic attack.

Intervention

Ticagrelor (180 mg loading dose, 90 mg twice daily thereafter) or clopidogrel (300 mg loading dose, 75 mg daily thereafter) on a background of aspirin

SUBMITTER: Wang Y 

PROVIDER: S-EPMC6549283 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature